Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682901 · ClinicalTrials.gov registry record · Phase 4
Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
A Phase 4 study, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
NCT02682901 is a Phase 4 study that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 84 participants.
The verdict
NCT02682901, a Phase 4 study, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
Study Summary
The main objective is to demonstrate the effects of early dopaminergic activation on the autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes. The primary endpoint is the effect of Bromocriptine QR on changes in autonomic function measured by assessing sympathetic and parasympathetic function using conventional measures of autonomic function, including power spectral analysis of heart rate as well as peripheral autonomic function using sudorimetry and laser scanning of peripheral microvascular autonomic control.
Interventions
- DRUG Placebo
- DRUG Cycloset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-10-05 |
| Est. Completion | 2018-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02682901
The ClinicalTrials.gov registry entry for NCT02682901 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02682901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02682901 about?
NCT02682901 is a clinical study titled "Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects". The main objective is to demonstrate the effects of early dopaminergic activation on the autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes. The primary endpoint is the effect of Bromocriptine QR on changes in autonomic function measured by assessing sympatheti...
What is the current status of trial NCT02682901?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2015-10-05. Estimated completion is 2018-11-15.
What interventions are being tested in trial NCT02682901?
The interventions under investigation include: Placebo (DRUG), Cycloset (DRUG).
Who is sponsoring clinical trial NCT02682901?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.